Ignite Creation Date:
2024-05-05 @ 4:55 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00342576
Status:
COMPLETED
Last Update Posted:
2019-07-18
First Post:
2006-06-19
Brief Title:
Host Response to Infection and Treatment in Lymphatic Filarial Disease in India
Sponsor:
National Institute of Allergy and Infectious Diseases NIAID
Organization:
National Institutes of Health Clinical Center CC
Study Overview
Official Title:
Host Response to Infection and Treatment in Lymphatic Filarial Disease Strongyloidiasis in India
Status:
COMPLETED
Status Verified Date:
2019-07-15
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients admitted on this protocol will have or be suspected of having one of the lymphatic filarial infections affecting humans After routine clinical evaluation they will be studied in depth immunologically and their blood cells andor serum will be collected to provide reagents eg specific antibodies T cell clones etc that will be used in the laboratory to address the broader questions of immunodiagnosis immunoregulation immunopathology and immunoprophylaxis Careful observations of the patients clinical and immunologic responses to therapy will be made as well as long-term follow-up of these changes It is anticipated both that the patients will receive optimal clinical care for their infections and that the specimens collected from them will prove to be valuable reagents for the laboratory studies of the immunologic responses unique to filarial or other helminthic infections
Detailed Description:
This study is designed to determine the presence of and the immune response to filarial and stronglyloides infections in an area endemic for both infections in South India This study will aim to examine the presence of filarial and Strongyloides stercoralis infection at a community level as well as in hospital settings After routine clinical evaluation and screening individuals enrolled in this protocol will be studied in depth immunologically and their blood cells andor serum will be collected to address the broader questions of immunodiagnosis immunoregulation and immunopathology Careful observations of the individual s clinical and immunologic responses to therapy will be made as well as long-term follow-up of these changes In addition to infected individuals this protocol will also be used to study individuals with filarial pathology and endemic normal individuals This will enable us to characterize the immunological profiles of infected uninfected and diseased individuals in an endemic area and provide greater insight into the pathogenesis of lymphatic filarial disease as well as the immunology of strongyloides infection
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| OH89-I-0048 | None | None | None |